Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China
TOF could be an effective therapeutic option for patients with BS who demonstrate resistance to TNFi or corticosteroids. Specifically, the <i>STAT3</i> rs2293152 GG polymorphism was associated with improved response to treatment, suggesting a genotype-influenced therapeutic efficacy.
Authors
- Wen Yin (ORCID: https://orcid.org/0000-0002-7467-2286)
- Yangyang Hu (ORCID: https://orcid.org/0000-0002-2700-5464)
- Pengcheng Li (ORCID: https://orcid.org/0000-0002-2258-2318)
- Xiong Zhang (ORCID: https://orcid.org/0000-0002-9214-396X)
- Jinhua Liu (ORCID: https://orcid.org/0000-0002-4128-1043)
- Hai Xu (ORCID: https://orcid.org/0000-0002-5664-6789)
- Jing Cai (ORCID: https://orcid.org/0000-0002-7699-3446)
- Yikai Yu
- Zhipeng Zeng
Institutions
- Yunnan University (CN)
- Wuhan No.1 Hospital (CN)
- Wuhan Union Hospital (CN)
- Wuhan Children's Hospital (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Hubei University (CN)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3899/jrheum.2024-0822
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00